Clinical Trial

Prospective Registry of Vertigo Due to Vertebrobasilar Transient Attacks.

Study acronym: UTRAVERA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Vertigo and dizziness are common neurological complaints in the emergency department and may represent a wide spectrum of etiologies, including vertebrobasilar transient neurological attacks (VB-TNAs). Distinguishing VB-TNAs, particularly vertebrobasilar transient ischemic attacks (VB-TIAs), from migraine-like and other non-vascular conditions is often challenging at first presentation due to the absence of specific biomarkers and overlapping clinical features. The UTRAVERA study is a multicenter, prospective, observational investigation designed to characterize the clinical features of patients presenting with acute transient vertigo or dizziness suspected to be VB-TNAs. The study will also evaluate diagnostic evolution over time, treatment responses, and prognostic factors associated with clinical outcomes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-12.
Trial Details
NCT Number NCT07421973
Lead Sponsor University of Sao Paulo General Hospital
Collaborators: Seoul National University Bundang Hospital, University of Zurich, University College, London, LMU Klinikum
Conditions Vertigo, Dizziness, TIA (Transient Ischemic Attack), Transient Neurologic Symptoms
Enrollment 400 participants
Start Date 2026-05-01
Primary Completion 2028-05-30 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-27